Cefiderocol Targeted Treatment for Multidrug-Resistant Gram-Negative Infections: An Observational Cohort Study

Area of Science:

• Infectious Diseases
• Pharmacology
• Critical Care Medicine

Background:

• Multidrug-resistant Gram-negative bacteria (MDR-GNB) pose a significant treatment challenge, especially for hospitalized and critically ill patients.
• Limited therapeutic options exist for severe MDR-GNB infections.

Purpose of the Study:

• To evaluate the effectiveness and safety of cefiderocol for treating MDR-GNB infections.
• To assess clinical success, mortality, recurrence, resistance, and adverse events associated with cefiderocol treatment.

Main Methods:

• Retrospective observational study of 80 adult patients receiving cefiderocol for ≥72 hours.
• Primary outcome: clinical success (survival and no recurrence at 30 days).
• Secondary outcomes: 30- and 90-day mortality, recurrence, resistance, and adverse events.

Main Results:

• Clinical success was achieved in 67.5% of patients.
• Common pathogens included Pseudomonas aeruginosa, Enterobacterales, and Stenotrophomonas maltophilia.
• 30-day mortality was 27.5%, 90-day mortality was 36.5%, and 5% experienced recurrence or serious adverse events.

Conclusions:

• Cefiderocol demonstrated favorable clinical outcomes and an acceptable safety profile in a cohort of critically ill patients.
• The study suggests cefiderocol is a valuable therapeutic option for severe MDR-GNB infections.
• Further research may explore its role in specific patient populations and infection types.